

Donna Niedzwiecki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4103058/publications.pdf>

Version: 2024-02-01

141
papers

5,483
citations

147801

31
h-index

85541

71
g-index

144
all docs

144
docs citations

144
times ranked

7665
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	7.4	670
2	Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of Clinical Oncology</i> , 2006, 24, 3535-3541.	1.6	664
3	Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. <i>Journal of Clinical Oncology</i> , 2007, 25, 3456-3461.	1.6	423
4	Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 754.	7.4	369
5	Impact of primary tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3504-3504.	1.6	249
6	Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803. <i>Journal of Clinical Oncology</i> , 2008, 26, 4109-4115.	1.6	245
7	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 164-173.	9.4	243
8	Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1702-1711.	6.3	163
9	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis. <i>JAMA Oncology</i> , 2018, 4, 783.	7.1	147
10	Phase I/II Study of Preoperative Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy in Patients With Locally Advanced Rectal Cancer: Cancer and Leukemia Group B 89901. <i>Journal of Clinical Oncology</i> , 2006, 24, 2557-2562.	1.6	126
11	CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer. <i>Gastroenterology</i> , 2014, 147, 637-645.	1.3	118
12	Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 345.	6.3	115
13	Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 3671-3677.	1.6	112
14	CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. <i>Journal of Clinical Oncology</i> , 2016, 34, 2736-2742.	1.6	84
15	A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. <i>Cancer</i> , 1991, 68, 965-969.	4.1	79
16	Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581. <i>Journal of Clinical Oncology</i> , 2011, 29, 3146-3152.	1.6	68
17	Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance). <i>PLoS ONE</i> , 2014, 9, e99816.	2.5	65
18	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1277.	7.4	63

#	ARTICLE	IF	CITATIONS
19	Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3598-3607.	1.6	60
20	Impact of smoking on patients with stage III colon cancer. <i>Cancer</i> , 2010, 116, 957-966.	4.1	57
21	A Novel Reduced-Intensity Conditioning Regimen for Unrelated Umbilical Cord Blood Transplantation in Children with Nonmalignant Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 326-336.	2.0	53
22	Marine ω -3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 438-445.	2.5	52
23	Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 3047-3053.	1.6	51
24	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2018, 36, 1112-1120.	1.6	50
25	Primary (1 st) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3503-3503.	1.6	49
26	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	5.9	48
27	Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4005-4005.	1.6	47
28	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2019, 25, 7497-7505.	7.0	44
29	Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1-1.	1.6	44
30	Insulin-like growth factor-1 is a radial cell-associated neurotrophin that promotes neuronal recruitment from the adult songbird ependyma/subependyma. , 1998, 36, 1-15.		43
31	Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3511-3511.	1.6	37
32	Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. <i>Clinical Colorectal Cancer</i> , 2013, 12, 233-238.	2.3	31
33	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA1-LBA1.	1.6	31
34	Socioeconomic Status, Not Race, Is Associated With Reduced Survival in Esophagectomy Patients. <i>Annals of Thoracic Surgery</i> , 2017, 104, 234-244.	1.3	29
35	Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4005-4005.	1.6	29
36	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	28

#	ARTICLE	IF	CITATIONS
37	Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. , 2020, 8, e001662.		28
38	Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS ONE, 2018, 13, e0199244.	2.5	25
39	Intense Immunochemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909. A Preliminary Report.. Blood, 2004, 104, 895-895.	1.4	25
40	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncology, 2020, 6, 1713.	7.1	24
41	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectrum, 2020, 4, pkz078.	2.9	22
42	Early 18F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence. International Journal of Radiation Oncology Biology Physics, 2020, 108, 969-976.	0.8	21
43	Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). Journal of Clinical Oncology, 2022, 40, 740-751.	1.6	20
44	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). Journal of the National Cancer Institute, 2019, 111, 170-179.	6.3	19
45	A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. Oncologist, 2017, 22, 107-114.	3.7	18
46	Treatment Outcomes in Anaplastic Thyroid Cancer. Journal of Thyroid Research, 2019, 2019, 1-11.	1.3	18
47	Use of Skeletal Muscle Index as a Predictor of Wait-List Mortality in Patients With End-Stage Liver Disease. Liver Transplantation, 2020, 26, 1090-1099.	2.4	18
48	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. Clinical Colorectal Cancer, 2013, 12, 95-102.	2.3	17
49	MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial. PLoS ONE, 2014, 9, e108483.	2.5	17
50	Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. European Journal of Cancer, 2019, 111, 82-93.	2.8	17
51	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. Journal of Clinical Oncology, 2017, 35, LBA1-LBA1.	1.6	17
52	Intrinsic radiomic expression patterns after 20 Gy demonstrate early metabolic response of oropharyngeal cancers. Medical Physics, 2021, 48, 3767-3777.	3.0	16
53	Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1227-1230.	2.5	15
54	Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2017, 35, 3504-3504.	1.6	15

#	ARTICLE	IF	CITATIONS
55	Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 4734-4744.	7.0	14
56	The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. <i>PLoS ONE</i> , 2018, 13, e0202272.	2.5	13
57	A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 909-917.	2.3	13
58	Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 465-e917.	3.7	13
59	A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3624-TPS3624.	1.6	13
60	Genetic variation determines VEGF-A plasma levels in cancer patients. <i>Scientific Reports</i> , 2018, 8, 16332.	3.3	10
61	Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2018, 2, pky017.	2.9	10
62	Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019, 123, 101-111.	2.8	10
63	Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2015, 33, 507-507.	1.6	10
64	Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. <i>American Journal of Roentgenology</i> , 2019, 213, 1232-1239.	2.2	9
65	A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 1032.	2.6	9
66	Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3503-3503.	1.6	9
67	Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3597-3597.	1.6	9
68	Phase I study of pazopanib plus TH-302 in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 611-619.	2.3	8
69	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa024.	2.9	8
70	Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. <i>JAMA Network Open</i> , 2020, 3, e2023500.	5.9	8
71	Primary Mediastinal (Thymic) Large B-Cell Lymphoma: Fidelity of Diagnosis Using WHO Criteria. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e464-e469.	0.4	7
72	Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET).. <i>Journal of Clinical Oncology</i> , 2021, 39, 369-369.	1.6	7

#	ARTICLE	IF	CITATIONS
73	Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival in CALGB 89803 (Alliance).. Journal of Clinical Oncology, 2017, 35, 585-585.	1.6	7
74	A phase I study of gemcitabine+dasatinib (gd) or gemcitabine+dasatinib+cetuximab (GDC) in refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2019, 83, 1025-1035.	2.3	6
75	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2021, 5, pkaa074.	2.9	6
76	Big Data, Small Effects. Journal of Clinical Oncology, 2016, 34, 1170-1171.	1.6	5
77	Predictors of Clinical Outcome After Treatment of Intracranial Aneurysms with the Pipeline Embolization Device. World Neurosurgery, 2019, 130, e666-e671.	1.3	5
78	Development and Implementation of an Educational Simulation Workshop in Fiberoptic Laryngoscopy for Radiation Oncology Residents. International Journal of Radiation Oncology Biology Physics, 2020, 108, 615-619.	0.8	5
79	The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1692-1695.	2.5	5
80	BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, TPS873-TPS873.	1.6	5
81	Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.. Blood, 2005, 106, 2896-2896.	1.4	5
82	Impact of Malnutrition on Outcomes in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Insertion. Digestive Diseases and Sciences, 2020, 65, 3332-3340.	2.3	4
83	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). JNCI Cancer Spectrum, 2021, 5, pkab034.	2.9	4
84	Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581.. Journal of Clinical Oncology, 2014, 32, 455-455.	1.6	4
85	Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 3548-3548.	1.6	4
86	American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance).. Journal of Clinical Oncology, 2017, 35, 10006-10006.	1.6	4
87	Effective Pain Control With Very Low Dose Palliative Radiation Therapy for Patients With Multiple Myeloma With Uncomplicated Osseous Lesions. Advances in Radiation Oncology, 2021, 6, 100729.	1.2	3
88	Outcome and Immune Reconstitution Following T Cell Depleted Nonmyeloablative Allogeneic Transplantation Using Matched Donors.. Blood, 2005, 106, 2036-2036.	1.4	3
89	Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.. Blood, 2006, 108, 2737-2737.	1.4	3
90	Multivariate Analysis of Patient and Graft Specific Factors among 330 Recipients of Unrelated Cord Blood Transplant (UCBT) To Predict Risk of Death from Opportunistic Infections in the First 6 Months after UCBT.. Blood, 2006, 108, 2860-2860.	1.4	3

#	ARTICLE	IF	CITATIONS
91	A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.. Journal of Clinical Oncology, 2018, 36, 3555-3555.	1.6	3
92	A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.. Journal of Clinical Oncology, 2018, 36, 4121-4121.	1.6	3
93	Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE).. Journal of Clinical Oncology, 2018, 36, 638-638.	1.6	3
94	Predictive and prognostic value of <i>HER2</i> gene expression and <i>HER2</i> amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2020, 38, 4086-4086.	1.6	3
95	Racial disparities in transjugular intrahepatic portosystemic shunt procedure outcomes. BMJ Open Gastroenterology, 2022, 9, e000747.	2.7	3
96	Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. JAMA Network Open, 2022, 5, e220145.	5.9	3
97	Cancer patient satisfaction with telehealth: Survey results from a large NCI-designated cancer institute.. Journal of Clinical Oncology, 2021, 39, 1579-1579.	1.6	2
98	Recumbent Total Skin Electron Beam Therapy. Advances in Radiation Oncology, 2021, 6, 100698.	1.2	2
99	Effect of Large Prostate Volume on Efficacy and Toxicity of Moderately Hypofractionated Radiotherapy In Patients with Prostate Cancer. Advances in Radiation Oncology, 2021, 7, 100805.	1.2	2
100	Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).. Journal of Clinical Oncology, 2016, 34, e15013-e15013.	1.6	2
101	Associations of physical activity with survival and progression in metastatic colorectal cancer: Results from CALGB 80405 (Alliance).. Journal of Clinical Oncology, 2017, 35, 659-659.	1.6	2
102	Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.. Journal of Clinical Oncology, 2020, 38, 4003-4003.	1.6	2
103	Quality of Life Associated with Open vs Minimally Invasive Pancreaticoduodenectomy: A Prospective Pilot Study. Journal of the American College of Surgeons, 2022, 234, 632-644.	0.5	2
104	Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer. Obstetrical and Gynecological Survey, 2008, 63, 94-96.	0.4	1
105	Quality in Cancer Care: An Assessment of the American College of Surgeons Commission on Cancer Quality Measures. Journal of the American College of Surgeons, 2017, 225, S125.	0.5	1
106	Impact of machine learning-directed on-treatment evaluations on cost of acute care visits: Economic analysis of SHIELD-RT.. Journal of Clinical Oncology, 2021, 39, 1509-1509.	1.6	1
107	Establishing ADC-Based Histogram and Texture Features for Early Treatment-Induced Changes in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 708398.	2.8	1
108	Sequential Topoisomerase I (Topo I) and Topoisomerase II (Topo II) Inhibitors in Relapsed/Refractory Aggressive NHL: Results of CALGN 59906, a Phase II Study of Doxorubicin and Topotecan.. Blood, 2004, 104, 2500-2500.	1.4	1

#	ARTICLE	IF	CITATIONS
109	A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405.. Journal of Clinical Oncology, 2015, 33, 3599-3599.	1.6	1
110	X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 687-687.	1.6	1
111	Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomized controlled trials.. Journal of Clinical Oncology, 2020, 38, 4533-4533.	1.6	1
112	Dose Dense, High Intensity Induction Therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem Cell Transplantation(AHSCT) for Mantle Cell Lymphoma (MCL).. Blood, 2004, 104, 913-913.	1.4	1
113	Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.. Journal of Clinical Oncology, 2017, 35, 3528-3528.	1.6	1
114	Topical sildenafil in the treatment of hand-foot syndrome and hand-foot skin reaction: A retrospective study.. Journal of Clinical Oncology, 2018, 36, e22095-e22095.	1.6	1
115	Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2022, 40, TPS6108-TPS6108.	1.6	1
116	Reply to L. Casadaban et al. Journal of Clinical Oncology, 2017, 35, 1373-1374.	1.6	0
117	Reply to L. Fornaro et al. Journal of Clinical Oncology, 2018, 36, 1179-1180.	1.6	0
118	1089 Hypophosphatemia in Patients With Alcoholic Hepatitis. American Journal of Gastroenterology, 2019, 114, S615-S616.	0.4	0
119	Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.. Journal of Clinical Oncology, 2021, 39, 3568-3568.	1.6	0
120	Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance).. Journal of Clinical Oncology, 2021, 39, 3588-3588.	1.6	0
121	RADI-09. Clinical factors associated with death after radiotherapy for brain metastases. Neuro-Oncology Advances, 2021, 3, iii19-iii19.	0.7	0
122	Classification of older adults who underwent lumbar-related surgery using preoperative biopsychosocial predictors and relationships with surgical recovery: An observational study conducted in the United States. Health and Social Care in the Community, 2021, , .	1.6	0
123	Dendritic and T Cell Subsets Correlate with the Development and Site of Acute GVHD Following Unrelated Cord Blood Transplantation. A Multivariate Analysis of Host, Graft, and Day+50 Immune Profile.. Blood, 2004, 104, 981-981.	1.4	0
124	Lung Transplantation Alters Esophageal Motility and is Associated with Abnormal pH Testing. American Journal of Gastroenterology, 2010, 105, S13-S14.	0.4	0
125	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. Blood, 2010, 116, 3523-3523.	1.4	0
126	A Comprehensive Comparison Immune Recovery In Adult Patients Following Allogeneic Umbilical Cord Blood, Matched Sibling and Matched Unrelated Donor Stem Cell Transplantation. Blood, 2010, 116, 2313-2313.	1.4	0

#	ARTICLE	IF	CITATIONS
127	The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 4065-4065.	1.4	0
128	A novel interaction of genotype, gender, and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803.. Journal of Clinical Oncology, 2012, 30, 452-452.	1.6	0
129	Abstract 4514: A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803. , 2012, , .		0
130	Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).. Journal of Clinical Oncology, 2014, 32, 448-448.	1.6	0
131	Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).. Journal of Clinical Oncology, 2014, 32, 11022-11022.	1.6	0
132	Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.. Journal of Clinical Oncology, 2015, 33, 3585-3585.	1.6	0
133	Deletions in HSP110 T17 and patient prognosis in stage III microsatellite instable (MSI) colon cancers: Findings from CALGB 89803 and NCCTG N0147.. Journal of Clinical Oncology, 2016, 34, e15148-e15148.	1.6	0
134	Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 3570-3570.	1.6	0
135	Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2019, 37, 3035-3035.	1.6	0
136	409â€¦A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO). , 2020, , .		0
137	Abstract 3285: Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance). , 2019, , .		0
138	Clinical Predictors of a Positive Ct Angiogram Study Used for the Evaluation of Acute Gastrointestinal Hemorrhage. Digestive Diseases and Sciences, 2022, , 1.	2.3	0
139	Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 3571-3571.	1.6	0
140	Predictive value of <i>MAOB</i> gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405.. Journal of Clinical Oncology, 2022, 40, 3580-3580.	1.6	0
141	Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2022, 40, 3553-3553.	1.6	0